163 related articles for article (PubMed ID: 37815978)
1. Automation, live-cell imaging, and endpoint cell viability for prostate cancer drug screens.
Lyles RDZ; Martinez MJ; Sherman B; Schürer S; Burnstein KL
PLoS One; 2023; 18(10):e0287126. PubMed ID: 37815978
[TBL] [Abstract][Full Text] [Related]
2. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
Patki M; Huang Y; Ratnam M
Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
[TBL] [Abstract][Full Text] [Related]
3. Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer.
Fahrenholtz CD; Rick FG; Garcia MI; Zarandi M; Cai RZ; Block NL; Schally AV; Burnstein KL
Proc Natl Acad Sci U S A; 2014 Jan; 111(3):1084-9. PubMed ID: 24395797
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer.
Singh KB; Ji X; Singh SV
Mol Cancer Ther; 2018 Oct; 17(10):2079-2090. PubMed ID: 30030299
[TBL] [Abstract][Full Text] [Related]
5. [Correlation between the expression of Pim-1 and androgen-deprivation therapy for prostate cancer].
Wang J; Quan CY; Chang WL; Shang ZQ; Jiang N; Li B; Niu YJ
Zhonghua Nan Ke Xue; 2015 Sep; 21(9):775-81. PubMed ID: 26552208
[TBL] [Abstract][Full Text] [Related]
6. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
Linder A; Larsson K; Welén K; Damber JE
Prostate; 2020 Aug; 80(11):799-810. PubMed ID: 32449815
[TBL] [Abstract][Full Text] [Related]
7. Antiandrogenic Effects of a Polyphenol in
Kudo Y; Endo S; Tanio M; Saka T; Himura R; Abe N; Takeda M; Yamaguchi E; Yoshino Y; Arai Y; Kashiwagi H; Oyama M; Itoh A; Shiota M; Fujimoto N; Ikari A
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430833
[TBL] [Abstract][Full Text] [Related]
8. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
Cheng Q; Butler W; Zhou Y; Zhang H; Tang L; Perkinson K; Chen X; Jiang XS; McCall SJ; Inman BA; Huang J
Eur Urol; 2022 May; 81(5):446-455. PubMed ID: 35058087
[TBL] [Abstract][Full Text] [Related]
9. Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer.
Begemann D; Wang Y; Yang W; Kyprianou N
Prostate; 2020 Sep; 80(12):926-937. PubMed ID: 32542812
[TBL] [Abstract][Full Text] [Related]
10. Exosomes Promote the Transition of Androgen-Dependent Prostate Cancer Cells into Androgen-Independent Manner Through Up-Regulating the Heme Oxygenase-1.
Zhang Y; Chen B; Xu N; Xu P; Lin W; Liu C; Huang P
Int J Nanomedicine; 2021; 16():315-327. PubMed ID: 33469288
[TBL] [Abstract][Full Text] [Related]
11. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
Moll JM; Hofland J; Teubel WJ; de Ridder CMA; Taylor AE; Graeser R; Arlt W; Jenster GW; van Weerden WM
Prostate; 2022 Apr; 82(5):505-516. PubMed ID: 35037287
[TBL] [Abstract][Full Text] [Related]
12. Activation of GRP/GRP-R signaling contributes to castration-resistant prostate cancer progression.
Qiao J; Grabowska MM; Forestier-Roman IS; Mirosevich J; Case TC; Chung DH; Cates JM; Matusik RJ; Manning HC; Jin R
Oncotarget; 2016 Sep; 7(38):61955-61969. PubMed ID: 27542219
[TBL] [Abstract][Full Text] [Related]
13. Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer.
Harris AE; Metzler VM; Lothion-Roy J; Varun D; Woodcock CL; Haigh DB; Endeley C; Haque M; Toss MS; Alsaleem M; Persson JL; Gudas LJ; Rakha E; Robinson BD; Khani F; Martin LM; Moyer JE; Brownlie J; Madhusudan S; Allegrucci C; James VH; Rutland CS; Fray RG; Ntekim A; de Brot S; Mongan NP; Jeyapalan JN
Front Endocrinol (Lausanne); 2022; 13():1006101. PubMed ID: 36263323
[TBL] [Abstract][Full Text] [Related]
14. Minnelide Inhibits Androgen Dependent, Castration Resistant Prostate Cancer Growth by Decreasing Expression of Androgen Receptor Full Length and Splice Variants.
Isharwal S; Modi S; Arora N; Uhlrich C; Giri B; Barlass U; Soubra A; Chugh R; Dehm SM; Dudeja V; Saluja A; Banerjee S; Konety B
Prostate; 2017 May; 77(6):584-596. PubMed ID: 28144973
[TBL] [Abstract][Full Text] [Related]
15. Targeting glutamine dependence with DRP-104 inhibits proliferation and tumor growth of castration-resistant prostate cancer.
Moon D; Hauck JS; Jiang X; Quang H; Xu L; Zhang F; Gao X; Wild R; Everitt JI; Macias E; He Y; Huang J
Prostate; 2024 Mar; 84(4):349-357. PubMed ID: 38084059
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with novel androgen receptor antagonists and statin for castration-resistant prostate cancer.
Nakayama H; Sekine Y; Oka D; Miyazawa Y; Arai S; Koike H; Matsui H; Shibata Y; Suzuki K
Prostate; 2022 Feb; 82(3):314-322. PubMed ID: 34843630
[TBL] [Abstract][Full Text] [Related]
17. Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer.
Chen X; Shao Y; Wei W; Zhu S; Li Y; Chen Y; Li H; Tian H; Sun G; Niu Y; Shang Z
Cell Death Dis; 2022 Nov; 13(11):927. PubMed ID: 36335093
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
19. Smoothened loss is a characteristic of neuroendocrine prostate cancer.
Wang L; Li H; Li Z; Li M; Tang Q; Wu C; Lu Z
Prostate; 2021 Jun; 81(9):508-520. PubMed ID: 33955576
[TBL] [Abstract][Full Text] [Related]
20. Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer.
Ferrari N; Granata I; Capaia M; Piccirillo M; Guarracino MR; Venè R; Brizzolara A; Petretto A; Inglese E; Morini M; Astigiano S; Amaro AA; Boccardo F; Balbi C; Barboro P
Cell Commun Signal; 2017 Dec; 15(1):51. PubMed ID: 29216878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
